Company News

Lonza and Chr. Hansen Form JV

Goal is to accelerate momentum in microbiome.

Author Image

By: Christine Esposito

Editor-in-Chief

Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a equally-controlled legal entity that will operate from its headquarters in Basel and have production facilities in Denmark and Switzerland. The joi...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters